Balancing the oncologic effectiveness versus the cardiotoxicity of anthracycline chemotherapy in childhood cancer

Steven D. Colan, Steven E Lipshultz, Stephen E. Sallan

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

One of the most complex issues in cancer treatment is the unavoidable conflict between administering cytotoxic agents with variable tumor selectivity and the resulting dose-dependent short- and long-term damage to normal tissues. Further, there is great uncertainty as to whether late outcomes from prior treatment protocols are relevant to the anticipated late outcomes from current protocols. Virtually all recipients of anthracycline therapy should be considered to have some degree of cardiotoxicity. However, the severity of cardiotoxicity, not its presence, should determine what actions are appropriate. Currently, changes in ejection fraction and other imaging or serologic biomarkers (singly or in combination) during therapy have weak predictive value for chronic cardiomyopathy after the end of therapy, and their clinical utility requires further verification. Cardiotoxicity justifying individual dose modification during therapy requires evidence that it improves survival. The low prior probability of congestive heart failure during anthracycline therapy with the current monitoring protocols means that the ejection fraction has an unacceptably low predictive value. As a result, continued reliance on published recommendations for withholding chemotherapy based on asymptomatic changes in ejection fraction increases the risk of treatment failure more than it decreases the likelihood of irreversible cardiac injury. However, abnormalities in ventricular size and function after the end of therapy do predict chronic, progressive cardiomyopathy and justify longitudinal monitoring. Here, we discuss the cardiotoxicity of some of these chemotherapeutic agents and provide a framework for deciding when the evidence of cardiotoxicity is strong enough to justify a change in management.

Original languageEnglish (US)
Pages (from-to)7-10
Number of pages4
JournalProgress in Pediatric Cardiology
Volume36
Issue number1-2
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Anthracyclines
Drug Therapy
Neoplasms
Cardiomyopathies
Therapeutics
Ventricular Function
Cytotoxins
Clinical Protocols
Cardiotoxicity
Treatment Failure
Uncertainty
Heart Failure
Biomarkers
Wounds and Injuries

Keywords

  • Cancer
  • Cardiomyopathy
  • Doxorubicin
  • Pediatrics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pediatrics, Perinatology, and Child Health

Cite this

Balancing the oncologic effectiveness versus the cardiotoxicity of anthracycline chemotherapy in childhood cancer. / Colan, Steven D.; Lipshultz, Steven E; Sallan, Stephen E.

In: Progress in Pediatric Cardiology, Vol. 36, No. 1-2, 2014, p. 7-10.

Research output: Contribution to journalArticle

Colan, Steven D. ; Lipshultz, Steven E ; Sallan, Stephen E. / Balancing the oncologic effectiveness versus the cardiotoxicity of anthracycline chemotherapy in childhood cancer. In: Progress in Pediatric Cardiology. 2014 ; Vol. 36, No. 1-2. pp. 7-10.
@article{ce5fc2b9a40745a6b41fa50b54d2325f,
title = "Balancing the oncologic effectiveness versus the cardiotoxicity of anthracycline chemotherapy in childhood cancer",
abstract = "One of the most complex issues in cancer treatment is the unavoidable conflict between administering cytotoxic agents with variable tumor selectivity and the resulting dose-dependent short- and long-term damage to normal tissues. Further, there is great uncertainty as to whether late outcomes from prior treatment protocols are relevant to the anticipated late outcomes from current protocols. Virtually all recipients of anthracycline therapy should be considered to have some degree of cardiotoxicity. However, the severity of cardiotoxicity, not its presence, should determine what actions are appropriate. Currently, changes in ejection fraction and other imaging or serologic biomarkers (singly or in combination) during therapy have weak predictive value for chronic cardiomyopathy after the end of therapy, and their clinical utility requires further verification. Cardiotoxicity justifying individual dose modification during therapy requires evidence that it improves survival. The low prior probability of congestive heart failure during anthracycline therapy with the current monitoring protocols means that the ejection fraction has an unacceptably low predictive value. As a result, continued reliance on published recommendations for withholding chemotherapy based on asymptomatic changes in ejection fraction increases the risk of treatment failure more than it decreases the likelihood of irreversible cardiac injury. However, abnormalities in ventricular size and function after the end of therapy do predict chronic, progressive cardiomyopathy and justify longitudinal monitoring. Here, we discuss the cardiotoxicity of some of these chemotherapeutic agents and provide a framework for deciding when the evidence of cardiotoxicity is strong enough to justify a change in management.",
keywords = "Cancer, Cardiomyopathy, Doxorubicin, Pediatrics",
author = "Colan, {Steven D.} and Lipshultz, {Steven E} and Sallan, {Stephen E.}",
year = "2014",
doi = "10.1016/j.ppedcard.2014.09.002",
language = "English (US)",
volume = "36",
pages = "7--10",
journal = "Progress in Pediatric Cardiology",
issn = "1058-9813",
publisher = "Elsevier Ireland Ltd",
number = "1-2",

}

TY - JOUR

T1 - Balancing the oncologic effectiveness versus the cardiotoxicity of anthracycline chemotherapy in childhood cancer

AU - Colan, Steven D.

AU - Lipshultz, Steven E

AU - Sallan, Stephen E.

PY - 2014

Y1 - 2014

N2 - One of the most complex issues in cancer treatment is the unavoidable conflict between administering cytotoxic agents with variable tumor selectivity and the resulting dose-dependent short- and long-term damage to normal tissues. Further, there is great uncertainty as to whether late outcomes from prior treatment protocols are relevant to the anticipated late outcomes from current protocols. Virtually all recipients of anthracycline therapy should be considered to have some degree of cardiotoxicity. However, the severity of cardiotoxicity, not its presence, should determine what actions are appropriate. Currently, changes in ejection fraction and other imaging or serologic biomarkers (singly or in combination) during therapy have weak predictive value for chronic cardiomyopathy after the end of therapy, and their clinical utility requires further verification. Cardiotoxicity justifying individual dose modification during therapy requires evidence that it improves survival. The low prior probability of congestive heart failure during anthracycline therapy with the current monitoring protocols means that the ejection fraction has an unacceptably low predictive value. As a result, continued reliance on published recommendations for withholding chemotherapy based on asymptomatic changes in ejection fraction increases the risk of treatment failure more than it decreases the likelihood of irreversible cardiac injury. However, abnormalities in ventricular size and function after the end of therapy do predict chronic, progressive cardiomyopathy and justify longitudinal monitoring. Here, we discuss the cardiotoxicity of some of these chemotherapeutic agents and provide a framework for deciding when the evidence of cardiotoxicity is strong enough to justify a change in management.

AB - One of the most complex issues in cancer treatment is the unavoidable conflict between administering cytotoxic agents with variable tumor selectivity and the resulting dose-dependent short- and long-term damage to normal tissues. Further, there is great uncertainty as to whether late outcomes from prior treatment protocols are relevant to the anticipated late outcomes from current protocols. Virtually all recipients of anthracycline therapy should be considered to have some degree of cardiotoxicity. However, the severity of cardiotoxicity, not its presence, should determine what actions are appropriate. Currently, changes in ejection fraction and other imaging or serologic biomarkers (singly or in combination) during therapy have weak predictive value for chronic cardiomyopathy after the end of therapy, and their clinical utility requires further verification. Cardiotoxicity justifying individual dose modification during therapy requires evidence that it improves survival. The low prior probability of congestive heart failure during anthracycline therapy with the current monitoring protocols means that the ejection fraction has an unacceptably low predictive value. As a result, continued reliance on published recommendations for withholding chemotherapy based on asymptomatic changes in ejection fraction increases the risk of treatment failure more than it decreases the likelihood of irreversible cardiac injury. However, abnormalities in ventricular size and function after the end of therapy do predict chronic, progressive cardiomyopathy and justify longitudinal monitoring. Here, we discuss the cardiotoxicity of some of these chemotherapeutic agents and provide a framework for deciding when the evidence of cardiotoxicity is strong enough to justify a change in management.

KW - Cancer

KW - Cardiomyopathy

KW - Doxorubicin

KW - Pediatrics

UR - http://www.scopus.com/inward/record.url?scp=84926098007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926098007&partnerID=8YFLogxK

U2 - 10.1016/j.ppedcard.2014.09.002

DO - 10.1016/j.ppedcard.2014.09.002

M3 - Article

AN - SCOPUS:84926098007

VL - 36

SP - 7

EP - 10

JO - Progress in Pediatric Cardiology

JF - Progress in Pediatric Cardiology

SN - 1058-9813

IS - 1-2

ER -